Dr. Leslie A. Andritsos, MD

Dr. Andritsos practices at University of New Mexico Hospital in Albuquerque, New Mexico, part of The University of New Mexico.

Dr. Andritsos' NPI, 1316919418, was assigned on February 2, 2006. Dr. Andritsos graduated from UTMB Health in 1999. Dr. Andritsos' New Mexico license number on file is MD2018-0620.

Dr. Andritsos' primary practice is University of New Mexico Hospital, at 2211 Lomas Boulevard NE, Albuquerque, NM 87106 in Bernalillo County. The practice phone is (505) 272-2111.

Dr. Andritsos' primary practice is University of New Mexico Hospital in Albuquerque, New Mexico, part of The University of New Mexico. The medical group on file is UNM Medical Group, Inc. Dmand AI also links Dr. Andritsos to 1 more group practice or clinic, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Andritsos practices, 2 sites in all. Vendor and product names are available with a free account.

Internal medicine is Dr. Andritsos' primary specialty in the NPI Registry, under taxonomy code 207RH0000X. The record also lists hematology. Dr. Andritsos is board certified in hematology by the American Board of Internal Medicine. Dmand AI has Dr. Andritsos' licenses on file in 4 states: New Mexico, Missouri, Ohio and Arizona.

Dmand AI lists chronic anemia, hiv/aids, insomnia, pancreatitis and purpura and thrombocytopenia among the conditions Dr. Andritsos treats.

CMS data shows 455 Medicare services from Dr. Andritsos across 5 procedure codes in 2024, for 120 Medicare patients. Medicare paid $28,363 for them.

CMS counts 120 Medicare patients who saw Dr. Andritsos in 2024. The largest group is 65 to 74, with 66 patients. 61% of them have high cholesterol, and 53% have high blood pressure. 10% are also on Medicaid. Their average risk score is 1.57, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Andritsos' median patient age at 73, with 53% women.

In 2024, Dr. Andritsos wrote 177 Medicare Part D claims for 46 patients. 65% of them were for generic drugs. CMS names the drug for 81 of them, across 5 drugs with 11 or more claims each, at $1,018,753 in total drug cost. In 2023, CMS named 27 claims across 2 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 90 out of 100 for Dr. Andritsos for performance year 2024, reported as part of a group. Dr. Andritsos accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Andritsos as offering telehealth.

Dmand AI links 150 papers to Dr. Andritsos, published from 2006 to 2025. 2017 was the busiest year, with 15. The most frequent topics are Leukemia, Lymphocytic, Chronic, B-Cell, Antineoplastic Agents and Piperidines. Dr. Andritsos has published most often in Blood. Dr. Andritsos' most frequent co-authors are John C. Byrd, MD, Kami J. Maddocks, MD and Michael Rhodes Grever, MD.

Dmand AI links Dr. Andritsos to 14 clinical trials, 4 of them phase 1 studies. 7 are still active or recruiting. Conditions studied include Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, B-Cell and Hodgkin Disease. National Cancer Institute (NCI) sponsors the most, 4.

CMS Open Payments shows 32 general payments to Dr. Andritsos from 9 drug and device companies from 2017 to 2023. Consulting fees make up the largest share, 82% of the total. AstraZeneca Pharmaceuticals LP paid the most, $22,353. It also lists 3 research payments totaling $2,172 in 2017.

Dmand AI lists 2 awards for Dr. Andritsos, most recently CMS Stage 1 EHR in 2013.

Dr. Andritsos graduated from UTMB Health in 1999. Dr. Andritsos is a member of AACR, ACP, ASCO and ASH.

Dr. Andritsos is in network with 18 carriers, including Aetna, Elevance and United Healthcare. PPO plans come from the most carriers, 11. Check the plan with the practice before a visit.